$1.47
4.26% yesterday
Nasdaq, Mar 31, 10:00 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Ironwood Pharmaceuticals Classifications & Recommendation:

Buy
83%
Hold
17%

Ironwood Pharmaceuticals Price Target

Target Price $8.67
Price $1.47
Potential
Number of Estimates 6
6 Analysts have issued a price target Ironwood Pharmaceuticals 2026 . The average Ironwood Pharmaceuticals target price is $8.67. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend Ironwood Pharmaceuticals to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ironwood Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the Ironwood Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 351.41 287.00
20.63% 18.33%
EBITDA Margin 28.30% 31.78%
40.51% 12.30%

6 Analysts have issued a sales forecast Ironwood Pharmaceuticals 2025 . The average Ironwood Pharmaceuticals sales estimate is

$287m
Unlock
. This is
18.33% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$376m 7.00%
Unlock
, the lowest is
$264m 24.87%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $351m 20.63%
2025
$287m 18.33%
Unlock
2026
$317m 10.48%
Unlock
2027
$258m 18.79%
Unlock
2028
$292m 13.20%
Unlock
2029
$335m 14.75%
Unlock

3 Analysts have issued an Ironwood Pharmaceuticals EBITDA forecast 2025. The average Ironwood Pharmaceuticals EBITDA estimate is

$91.2m
Unlock
. This is
15.52% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$101m 6.07%
Unlock
, the lowest is
$85.2m 21.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $99.5m 52.78%
2025
$91.2m 8.30%
Unlock
2026
$82.6m 9.47%
Unlock
2027
$58.0m 29.75%
Unlock
2028
$109m 87.93%
Unlock
2029
$153m 40.37%
Unlock

EBITDA Margin

2024 28.30% 40.51%
2025
31.78% 12.30%
Unlock
2026
26.04% 18.06%
Unlock
2027
22.52% 13.52%
Unlock
2028
37.39% 66.03%
Unlock
2029
45.74% 22.33%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.01 0.04
100.16% 300.00%
P/E 33.18
EV/Sales 2.57

4 Analysts have issued a Ironwood Pharmaceuticals forecast for earnings per share. The average Ironwood Pharmaceuticals EPS is

$0.04
Unlock
. This is
300.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.21 2,000.00%
Unlock
, the lowest is
$-0.21 2,200.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.01 100.16%
2025
$0.04 300.00%
Unlock
2026
$0.22 450.00%
Unlock
2027
$0.36 63.64%
Unlock

P/E ratio

Current 130.56 9,916.54%
2025
33.18 74.59%
Unlock
2026
6.51 80.38%
Unlock
2027
3.92 39.78%
Unlock

Based on analysts' sales estimates for 2025, the Ironwood Pharmaceuticals stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.10 53.13%
2025
2.57 22.21%
Unlock
2026
2.32 9.49%
Unlock
2027
2.86 23.14%
Unlock
2028
2.53 11.66%
Unlock
2029
2.20 12.85%
Unlock

P/S ratio

Current 0.64 79.08%
2025
0.79 22.44%
Unlock
2026
0.71 9.49%
Unlock
2027
0.88 23.15%
Unlock
2028
0.77 11.66%
Unlock
2029
0.67 12.85%
Unlock

Current Ironwood Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked Jan 30 2025
Craig-Hallum
Locked
Locked
Locked Jan 22 2025
Leerink Partners
Locked
Locked
Locked Sep 09 2024
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
Jan 30 2025
Locked
Craig-Hallum:
Locked
Locked
Jan 22 2025
Locked
Leerink Partners:
Locked
Locked
Sep 09 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today